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Characterization of a New Form of
Inherited Hypercholesterolemia
Familial Recessive Hypercholesterolemia
G. Zuliani, M. Arca, A. Signore, G. Bader, S. Fazio, M. Chianelli, S. Bellosta, F. Campagna,
A. Montali, M. Maioli, A. Pacifico, G. Ricci, R. Fellin
Abstract—We previously described a Sardinian family in which the probands had a severe form of hypercholesterolemia,
suggestive of familial hypercholesterolemia (FH). However, low density lipoprotein (LDL) receptor activity in
fibroblasts from these subjects and LDL binding ability were normal. The characteristics of the pedigree were consistent
with an autosomal recessive trait. Sitosterolemia and pseudohomozygous hyperlipidemia were ruled out. A second
Sardinian kindred with similar characteristics was identified. Probands showed severe hypercholesterolemia, whereas
their parents and grandparents were normolipidemic. FH, familial defective apoprotein (apo) B, sitosterolemia, and
cholesteryl ester storage disease were excluded by in vitro studies. We addressed the metabolic basis of this inherited
disorder by studying the in vivo metabolism of LDL in 3 probands from these 2 families. 125I-LDL turnover studies
disclosed a marked reduction in the fractional catabolic rate (0.1960.01 versus 0.3660.03 pools per day, respectively;
P,0.001) and a significant increase in the production rate [20.764.4 versus 14.062.4 mg z kg21 z d21, respectively;
P,0.01] of LDL apoB in the probands compared with normolipidemic controls. We then studied the in vivo
biodistribution and tissue uptake of 99mtechnetium-labeled LDL in the probands and compared them with those in normal
controls and 1 FH homozygote. The probands showed a significant reduction in hepatic LDL uptake, similar to that
observed in the FH homozygote. A reduced uptake of LDL by the kidney and spleen was also observed in all patients.
Our findings suggest that this recessive form of hypercholesterolemia is due to a marked reduction of in vivo LDL
catabolism. This appears to be caused by a selective reduction in hepatic LDL uptake. We propose that in this new lipid
disorder, a recessive defect causes a selective impairment of LDL receptor function in the liver. (Arterioscler Thromb
Vasc Biol. 1999;19:802-809.)
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Several conditions have been identified causing severeprimary hypercholesterolemia.1 The best characterized
are familial hypercholesterolemia (FH) and familial defective
apoB (FDB). FH is an autosomal dominant disease caused by
mutations in the LDL receptor (LDLR) gene.2 The LDLR is
a cell surface transmembrane protein that mediates the
specific uptake of plasma LDL. Receptor defects markedly
impair LDL catabolism, and FH patients typically show
severe elevations of plasma LDL cholesterol (LDL-C), ten-
don xanthomas, and premature coronary atherosclerosis.3
FDB is a genetic disorder caused by point mutations in the
gene encoding for apoB100 that reduces the binding ability of
LDL particles to the LDLR; as a consequence, LDL removal
is reduced, and affected individuals develop high plasma
cholesterol concentrations.4 Two other rare, autosomal reces-
sive diseases, sitosterolemia and cholesteryl ester storage
disease (CESD), can result in severe hypercholesterolemia.
Sitosterolemia is characterized by an accumulation of plant
sterols, mainly b-sitosterol, in the plasma,5 whereas CESD
results from a massive deposition of cholesteryl esters in most
tissues due to a deficient lysosomal acid lipase (LAL)
activity.6
We recently described an unusual pedigree in which
several cases of severe primary hypercholesterolemia and/or
premature sudden death were present.7 The probands showed
the clinical features of FH homozygotes, including severely
elevated plasma LDL-C, tuberous and tendon xanthomata,
and premature atherosclerosis. However, the LDLR activity
measured in skin fibroblasts was normal, as was LDL binding
ability. Haplotype segregation analysis further excluded in-
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volvement of the LDLR and apoB genes in the pathogenesis
of the disease. Consanguinity, absence of vertical transmis-
sion, and bimodal distribution of plasma cholesterol levels in
the kindred were consistent with an autosomal recessive trait.
In this report, we describe 2 other subjects with similar
characteristics belonging to a second kindred, and we inves-
tigated the metabolic mechanisms underlying this lipid dis-
order. To this aim, the in vivo kinetic parameters and the
tissue distributions of radiolabeled, autologous LDL were
evaluated in 3 probands from the 2 kindreds. Our results
demonstrate that this form of hypercholesterolemia is due to
a marked reduction in LDL catabolism caused by a selective
reduction of LDL uptake by the liver. We hypothesize that a
recessive defect in these patients selectively causes an im-
pairment of LDLR function in the liver.
Methods
Patients
Table 1 summarizes the clinical and biochemical characteristics of
the subjects included in this study. The 2 probands of kindred No. 1
(G.F.C. and J.C.) have been previously described in detail.7 Probands
of kindred No. 2 (A.P. and G.P.) are of Sardinian origin and were
referred to the Lipid Clinic of the University of Rome for evaluation
of primary hypercholesterolemia (ranging between 400 and 600
mg/dL) and tendon xanthomata. A.P. had exertional angina, and a
coronary angiogram showed 3-vessel disease; G.P. had no clinical
signs of coronary atherosclerosis. Neither showed abnormal liver or
endocrine function tests. At the time of the LDL turnover study,
G.F.C. and A.P. were taking cardiovascular medication (aspirin and
nitrates). For comparison purposes, 1 homozygous FH patient
(H.F.H.) and 2 groups of normocholesterolemic controls were
studied. H.F.H. is a 23-year-old Sardinian male who is homozygous
for the FH-Elverum mutation.8 His LDLR activity in cultured skin
fibroblasts was ,5% of normal. For ethical reasons, in all patients
cholesterol-lowering treatment, including LDL apheresis (G.F.C.,
J.C., and H.F.H.), was suspended for only 40 days before the study.
The control group for the 125I-LDL turnover study consisted of 5
young, healthy, normocholesterolemic individuals (4 males and 1
female; mean age, 27.5 years). The control group for the 99mTc-LDL
metabolic study was composed of 12 middle-aged, normocholester-
olemic individuals (10 males and 2 females; mean age, 58.5 years);
3 of them showed elevated plasma triglycerides, but none were
taking lipid-lowering medications. All subjects agreed to participate
in the metabolic studies and gave their informed, written consent.
Cell Culture Studies
LDLR Activity Assay
In vitro LDLR activity was determined in probands A.P. and G.P. by
evaluating the specific 125I-LDL internalization and degradation in
confluent cultured fibroblasts from skin biopsies, as previously
described.7
Cellular Metabolism of Cholesterol
Intracellular accumulation of [3H]cholesteryl esters was evaluated
after incubation of skin fibroblasts of proband G.P. with recombinant
[3H]cholesterol-enriched human LDL ([3H]rLDL). Skin fibroblasts
from a normolipidemic subject and an LDLR-negative FH homozy-
gote were used as controls. [3H]rLDL was prepared according to
Brown et al.9 In brief, 20 mCi of [3H]cholesteryl linoleate was dried
under an N2 stream and resuspended in 200 mL of acetone. Two
milliliters of lipoprotein-deficient serum (LPDS) was added as a
source of cholesterol ester transfer protein, and the acetone was
evaporated under N2. LPDS was prepared as follows. Twenty
milliliters of human blood was adjusted to a density of 1.210 g/mL
and centrifuged (100 000 rpm) at 4°C for 4 hours in a Beckman
table-top TL100 centrifuge. LPDS was dialyzed for 24 hours at 4°C
against 150 mmol/L NaCl and 0.3 mmol/L EDTA, pH 7.4. Two
milligrams of LDL was added to the [3H]cholesteryl linoleate/LPDS
mixture in an N2 atmosphere and then incubated for 5 to 6 hours at
37°C in a shaking water bath. The density of the solution was
adjusted to 1.070 g/mL by adding KBr, and the mixture was topped
off with a d51.063 g/mL solution. rLDLs were reisolated by
ultracentrifugation for 2 hours at 12°C and 100 000 rpm. Isolated
rLDLs were purified through passage on a PD-10 column (Sephadex
G-25 M, Pharmacia). The protein concentration of rLDL was
determined by the Lowry method,10 whereas free and esterified
cholesterol levels were measured by enzymatic methods; rLDL
specific activity was also calculated.
Genetic Analysis
Genomic DNA Preparation
Blood samples from probands A.P. and G.P. were collected in 10-mL
tubes containing Na-EDTA and stored at 220°C. Genomic DNA
was extracted by the salting-out method11 and stored in Tris-EDTA
buffer (10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 8.0).
TABLE 1. Clinical and Biochemical Characteristics of Probands, FH Homozygote, and Control Subjects
Subjects Age, y Sex BMI
Plasma Lipids, mg/dL Fibroblast
LDLR
Activity* FDB b-Sitosterolemia CESDTC TG LDL-C HDL-C
Kindred No. 1
GFC 29 M 23.1 581 86 508 56 80 Absent Absent NE
JC 26 F 19.6 434 84 377 40 70 Absent Absent NE
Kindred No. 2
AP 45 F 25.9 627 208 550 36 80 Absent Absent NE
GP 39 M 22.0 450 98 372 58 85 Absent Absent Absent
FH homozygote* 23 M 24.0 698 200 625 33 ,5 NE NE NE
Controls (1)
(n55)
27.5 (9.7) 4M, 1F 24.4 (1.3) 210.0 (49.1) 88.2 (24.8) 132.7 (52.3) 49.0 (12.0) NE NE NE NE
Controls (2)
(n512)
58.5 (7.1) 10M, 2F 25.4 (3.9) 233.7 (53.1) 197.6 (80.1) 153.7 (44.1) 46.5 (16.5) NE NE NE NE
BMI indicates body mass index; TC, total cholesterol; TG, total triglycerides; and NE, not evaluated.
125I-LDL uptake and degradation are % of normal values. FDB refers to the apoB 3500 mutation. LDL-C reflects cholesterol concentration in the 1.019 to 1.063
g/mL density fraction. Controls (1) and (2) are control groups for 125I-LDL and 99mTc-LDL metabolic studies, respectively. Data for control subjects are reported as
mean6SD.
*Plasma lipid values are those at the time of diagnosis. During the LDL turnover study, average TC and LDL-C values were 502 and 446 mg/dL, respectively.
Zuliani et al March 1999 803
 at UniversitÃ  degli Studi di Milano on October 22, 2012http://atvb.ahajournals.org/Downloaded fro  
LDLR Gene Analysis
A combination of polymerase chain reaction (PCR), single-strand
conformation polymorphism (SSCP), and direct sequencing was
used to screen the LDLR gene in probands from kindred No. 2. The
promoter region and each exon of the LDLR gene were amplified
from genomic DNA by using 25-bp primers, and the fragment was
analyzed by the SSCP method. In brief, 0.1 mg genomic DNA was
amplified in 20 mL (final volume) containing 1.75 mmol/L of each
oligonucleotide primer, 50 mmol/L of each dNTP, 50 mmol/L KCl,
1.5 mmol/L MgCl2, 10 mmol/L Tris-HCl (pH 8.3), 10 mCi of
[32P]CTP (3000 Ci/mmol), and 2 U of Taq DNA polymerase. Each
PCR was subjected to 30 cycles at 94°C for 1 minute and 68°C for
5 minutes in a thermocycler (Perkin Elmer Cetus). One microliter of
the PCR mixture was diluted in 30 mL of formamide dye (98%
vol/vol; 50 mmol/L Na-EDTA, 0.01% wt/vol xylene cyanol, and
0.01% wt/vol bromophenol blue) and boiled for 5 minutes. A 3-mL
aliquot was subjected to electrophoresis (250 V for 16 hours at room
temperature) on a 6% to 7% nondenaturing gel in 23 Tris/borate/
EDTA and 10% glycerol (EM Science). Each gel was dried and
exposed to XAR-5 film for 6 to 24 hours at 270°C. To identify the
sequence variation responsible for abnormal SSCP patterns, DNA
fragments were directly sequenced using a modification of the
procedure of Lee.12
Detection of Defective Apo B-100
Classic FDB (apoB 3500) was detected by PCR and MspI restriction
enzyme digestion as previously described.4 Direct sequencing of
1000 bases around codon 3500 of the apoB gene was also performed
by following standard methods.12 The ability of LDL to bind to the
LDLR was further examined by an in vitro cell surface binding
assay, as previously described.7 In brief, LDL from proband G.P.
was isolated and used in competition experiments on normal human
fibroblasts against 2 mg/mL of 125I-LDL obtained from normal
subjects.
In Vivo Study of LDL Metabolism
125I-LDL Turnover Study
LDL turnover studies were performed at the University of Rome
(Rome, Italy) for probands J.C. and A.P. and at the National
Institutes of Health (NIH, Bethesda, Md) for proband G.F.C. and
following similar protocols.13,14 The studies had been approved by
the appropriate ethics committees at both institutions. In brief, LDL
(1.019 to 1.063 g/mL) was isolated from 30 to 50 mL of blood by
sequential ultracentrifugation, and '2 to 4 mg of dialyzed LDL was
radioiodinated by the McFarlane method as adapted for lipopro-
teins.15 The LDL preparation was sterilized by filtration through a
0.22-mm Millipore filter and tested for pyrogenicity by a Limulus
assay. Probands were instructed to follow a standard diet13 and
received 400 mg daily of KI to inhibit thyroid uptake. After 5 or 6
days, the probands were admitted to the metabolic ward and injected
with 10 to 20 mCi of autologous 125I-LDL; proband G.F.C. also
received homologous 131I-LDL obtained from a normolipidemic
control volunteer. After the injection, G.F.C. remained in the
metabolic ward at the NIH until the end of the study; J.C. and A.P.
were sampled for 4 hours as inpatients and then completed the study
as outpatients. Blood samples were collected after 10 minutes; at 1,
2, 4, and 24 hours; and then on days 2, 3, 4, 6, 8, 10, 12, and 14 after
injection to determine radioactivity (Packard Cobra gamma counter).
A radioisotope-decay curve was constructed, and the fractional
catabolic rate (FCR) for LDL apoB was estimated using a multiex-
ponential computer curve-fitting program (SAAM II).16 The curves
were consistently biexponential and corresponded to a bicompart-
mental model.17 The plasma pool size of LDL apoB was estimated as
previously described.13,14 LDL apoB production rate was then
calculated as the product of FCR and pool size and expressed as
milligrams of LDL apoB produced per day, normalized for body
weight.
Biodistribution of 99mTc-LDL
Native LDL preparations were radiolabeled with 99mTc after reduc-
tion of technetium atoms with sodium dithionite, as previously
described.18 In brief, 1 to 2 mg LDL was mixed with 40 to 50 mCi
of [99mTc]pertechnetate solution; 0.1 mL of 0.5 mol/L glycine buffer,
pH 10, containing 10 mg sodium dithionite was then added. The
mixture was gently mixed and incubated for 30 minutes at room
temperature. After incubation, 99mTc-LDL was separated from free
99mTc by gel filtration chromatography on a PD-10 column (Seph-
adex G-50, Pharmacia) and 0.1 mol/L NaHCO3 in saline (pH 8).
LDLs were eluted with the void volume. Labeled LDLs were
sterilized by filtration through a 0.22-mm Millipore filter. Each
patient was positioned supinely under the collimator of an Elscint
SP4 gamma camera, and 10 mCi of 99mTc-LDL was injected
intravenously as a bolus. Dynamic gamma-camera images of the
chest and upper abdomen were acquired every 15 seconds for the
first 60 minutes. Static anteroposterior images of the abdomen were
also acquired at 1, 4, and 24 hours after injection. Blood time-activity
curves were generated from the dynamic images with subsequent
biexponential fitting to obtain the half-life of the slow distribution
phase (S1) and the half-life of the rapid distribution phase (S2). From
the static images, we drew regions of interest (ROIs) over the heart,
liver, spleen, and kidneys, and time-activity curves were generated
after normalization for injected dose, isotope decay, and ROI area. In
particular, total liver uptake was calculated by drawing an ROI over
the whole organ and measuring total liver radioactivity (expressed in
counts per minute). By using an internal standard, counts were than
converted to activity (MBq), and liver uptake was expressed as a
percentage of the injected dose (data not shown). Liver size was
estimated as the number of pixels within the ROI area. Unitary liver
uptake was calculated by dividing the total liver uptake by the liver
size, thus allowing the comparison of 99mTc-LDL liver uptake in
subjects with different liver sizes.
Plasma Lipid and Lipoprotein Measurements
Blood samples were collected in the morning after an overnight fast
in EDTA-containing tubes. Plasma was immediately separated by
low-speed centrifugation, and total cholesterol, triglycerides, and
HDL-C were determined by standard methods.19–21 During the
125I-LDL turnover study, lipoproteins were quantified in the plasma
samples taken on days 1, 4, 8, 12, and 14 of the turnover period. The
VLDL1IDL (d,1.019 g/mL) and LDL (d51.019 to 1.063 g/mL)
fractions were obtained by sequential ultracentrifugation, as de-
scribed13; cholesterol was measured in the VLDL1IDL and 1.019
g/mL infranatant fractions, and the concentrations were corrected for
total recoveries. Plasma LDL-C concentrations were calculated as
the difference between the 1.019 g/mL infranatant cholesterol and
HDL-C. Cholesterol and total protein (apoB) were also assayed in
isolated LDL, and the plasma concentrations of LDL apoB were
derived by multiplying the cholesterol-to–apoB ratio in isolated LDL
by the absolute plasma concentration of LDL-C, determined as
described above.13
Other Laboratory Measurements
The serum sterol fraction was subjected to gas-liquid chromato-
graphic analysis, as reported.7 Measurements of LAL activity in
proband G.P. (kindly performed by Dr R. Anderson at the Bowman
Gray School of Medicine, Winston-Salem, NC) was carried out
using both the [3H]triolein and [14C]oleate methods and following a
previously described procedure.22 Apo E genotyping was determined
according to Hixon and Vernier.23
Statistical Analysis
Data were assessed for significance with Student’s unpaired, 2-tailed
t test. In all cases, statistical significance was set at P,0.05. Analysis
was carried out using the Stat-View for Macintosh package.
Results
Cellular and Genetic Studies in Kindred No. 2
The pedigree of family No. 2 spanning 5 generations is shown
in Figure 1. Besides the probands (IV-2, A.P.; and IV-3,
G.P.), 6 other family members were tested for plasma lipid
and lipoprotein concentrations (III-1, III-2, III-19, IV-4, IV-6,
and V-1). Subject III-19 presented with severe hypercholes-
terolemia (520 mg/dL), but the others showed total choles-
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terol levels ,95th age-matched percentile of cholesterol
distribution in the Italian population. In particular, the father
(III-1) showed total cholesterol levels of 257 mg/dL and
the mother (III-2), 245 mg/dL. The mother after the time
of measurement showed poorly compensated type II non–
insulin-dependent diabetes mellitus (blood glucose 170
mg/dL). An accurate anamnesis revealed 3 other cases of
severe hypercholesterolemia in the family (III-7, III-10, and
III-23) with reported values .500 mg/dL. Subject III-19
showed evidence of coronary artery disease, whereas subject
III-10 died of a documented myocardial infarction at the age
of 50 years. Like kindred No. 1,7 pedigree No. 2 was
characterized by the absence of vertical transmission of the
hypercholesterolemic trait and by the presence of consan-
guinity between the parents of affected individuals.
To determine whether hypercholesterolemia in this kindred
was due to FH, we first measured LDLR activity in cultured
fibroblasts. In both probands, 125I-LDL internalization was
between 80% and 100% of the normal range (Table 1). These
values were not compatible with the diagnosis of FH, in
which LDLR activity is usually ,40% to 60% of normal. It
has been suggested that mutations in the cytoplasmic tail of
the LDLR gene may produce an FH phenotype that is
undetectable by a 125I-LDL study in isolated fibroblast.24 To
exclude this possibility, we performed SSCP analysis of exon
17 (coding for the cytoplasmic tail of LDLR) as well as of
other exons and the promoter of the LDLR gene (data not
shown). Other than common polymorphisms, this analysis
did not disclose any alteration in the DNA sequences, once
again suggesting that structural defects in the LDLR gene
were not the cause of this form of hypercholesterolemia.
We also ruled out the possibility of defective binding of
LDL by excluding the presence of FDB and other mutations
near the binding domain of the apoB gene, as well as by
demonstrating that LDL particles isolated from proband G.P.
were able to compete normally with control LDL (data not
shown).
Plasma concentrations of sitosterol in A.P. and G.P. were
0.78 and 0.62 mg/dL, respectively. These values were within
the normal range (0.17 to 0.78 mg/dL), thus allowing us to
exclude the presence of sitosterolemia. Measurements of
LAL activity were performed for proband G.P., and these
analyses showed values of 220 (pmol/h)/mg cell protein by
the triolein method and 207 (nmol/h)/mg cell protein by the
oleate method. Both values were within the normal limits.25
The results of the experiments carried out with [3H]rLDL
are reported in Figure 2. The amount of [3H]cholesterol
incorporated into cellular cholesteryl esters in cultured fibro-
blasts from proband G.P. was similar to that observed in
normal fibroblasts at all [3H]rLDL concentrations in the
medium. As expected, the ability to metabolize [3H]choles-
terol was completely abolished in the fibroblasts obtained
from the receptor-negative FH homozygote. These data
provide additional strong support for the observation that
LDL uptake was not impaired in the proband’s fibroblasts, an
observation incompatible with the diagnosis of FH. Further-
Figure 1. Pedigree of family No. 2. The 2 probands are indicated by arrows.
Figure 2. Accumulation of [3H]cholesteryl esters
in cultured skin fibroblasts obtained from the
proband G.P. (—f—), the homozygous FH
patient (—M—), and the normal subject (—F—)
after incubation with different concentration of
[3H]rLDL. Experiments were carried out as
described in Methods.
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more, these experiments demonstrated the ability of the
proband’s fibroblasts to esterify cholesterol to a normal
extent.
In Vivo Metabolic Studies
Composition and in vivo kinetic parameters of LDL in the 3
probands are shown in Table 2 and are compared with those
obtained in 5 age-matched, normolipidemic controls. The
mean FCR (0.3660.03 pool/d) and production rate (14.062.4
mg z kg21 z d21) of LDL apoB in controls were very similar to
values previously reported in young adults.26 As expected,
probands showed markedly elevated plasma concentration of
LDL apoB, which were 1.6 to 3 times higher than in controls.
Moreover, LDL particles in probands G.F.C. and J.C. ap-
peared to be significantly cholesterol enriched, as suggested
by the high LDL-C-to–apoB ratio (2.10 and 1.76, respec-
tively, compared with 1.4060.11 in controls). The FCRs for
LDL apoB were significantly (P,0.001) reduced in all
probands and were '50% lower than control values. Individ-
ual figures ranged from 0.18 to 0.21 pool/d and were only
slightly higher than those typically seen in FH homozy-
gotes.26 In the turnover study, proband G.F.C. was simulta-
neously injected with autologous 125I-LDL and homologous
131I-LDL. Both tracers showed a similar, marked reduction in
the FCR (data not shown), further confirming the absence of
binding defects in LDL. The probands also showed increased
LDL apoB production rates, but although these values were
higher than in controls (P,0.01), they were lower than those
typically seen in FH homozygotes.26 Nevertheless, we ob-
served wide differences among probands; indeed, whereas the
LDL apoB production rate in J.C. (15.1 mg z kg21 z d21) was
within the normal range, in G.F.C. and A.P. it was .95th
percentile of control subjects (23.4 and 22.0 mg z kg21 z d21,
respectively).
The tissue distributions of autologous 99mTc-LDL in the
probands, the homozygous FH patient, and the normal con-
trols are shown in Figure 3. As confirmed by the data
obtained in the 125I-LDL turnover study, the plasma half-life
of 99mTc-LDL (estimated by the biexponential fitting of the
heart time-activity curves) was significantly longer in all
probands compared with controls and very similar to that
obtained in the FH homozygote (A). Half-life values of
(1) and (2) were 189.4 minutes for G.F.C., 178.4 minutes for
J.C., and 182.6 minutes for A.P., versus 110.1625.7 minutes
for controls.
So far as the 99mTc-LDL tissue uptake is concerned, the
probands showed a severe reduction in liver uptake (B)
compared with controls. This reduction was already signifi-
cant at early time points (P,0.05) and was of the same
magnitude as that observed in the FH homozygous subject.
After 24 hours, 3- to 10-fold less radioactivity was taken up
by the liver in the probands compared with controls
(P,0.001). Even though the probands and patient H.F.H.
showed 1.6 to 3 times higher LDL concentrations than
TABLE 2. Kinetic Parameters of LDL (125I-LDL) Metabolism
Parameters
Probands Controls
J.C. G.F.C. A.P. (n55)
LDL-C, mg/dL 509.0 339.0 461.0 132.7652.3
LDL apoB, mg/dL 289.0 162.5 322.4 100.2626.5
FCR, pools/d 0.18 0.20 0.21 0.3660.03
Production rate, (mg/kg)/d 23.4 15.1 22.0 14.062.4
LDL-C/apoB 1.76 2.10 1.43 1.4060.11
Data for control subjects are reported as mean6SD.
Figure 3. Biodistributions of autologous 99mTc-LDL in the heart (A), liver (B), spleen (C), and kidneys (D) in study patients. Data are
reported as percentage of radioactive dose injected corrected for the area of ROI. M indicates controls; , proband J.C.; , proband
G.F.C.; E, proband A.P.; and F, the homozygote FH patient.
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normals, their liver uptake of LDL was 3- to 10-fold less,
indicating a much greater reduction than that predicted
simply on the basis of the dilution of the tracer in the larger
LDL pool of the patients. In the hypercholesterolemic pa-
tients, moreover, liver uptake of 99mTc-LDL peaked within 4
to 6 hours and then reached a plateau, whereas in the controls,
it showed a steady increase up to 24 hours. The spleen and
kidney also showed reduced uptake of 99mTc-LDL in the
probands compared with controls (C and D). At 2 and 4
hours, no significant differences were found between patients
and controls, but at 24 hours after injection, kidney and
spleen 99mTc-LDL uptake was significantly lower in patients
(P,0.05). Kidney uptake in proband A.P. and in the FH
patient was completely abolished. Unlike that for the liver,
the 99mTc-LDL activity curves of these organs did not suggest
the presence of a specific, saturable mechanism of uptake.
Finally, by comparing in different organs the time-activity
curves before and after normalization of radioactivity per
organ area, we observed that the total liver uptake and the
unitary liver uptake were both reduced in G.F.C. and J.C.,
whereas the total liver uptake was normal in A.P. and in the
FH homozygote, despite a reduced unitary uptake. This
observation suggests that in these 2 subjects, liver hypertro-
phy and the increased Kupffer cell uptake compensated for
the hepatocyte defect; G.F.C. and J.C. also had increased liver
size, but it was not sufficient to compensate for the hepato-
cyte defect.
Discussion
This article reports the metabolic characteristics of an unusual
form of familial hypercholesterolemia that was detected in 2
families of Sardinian origin. A common feature of the 2
families was that the probands exhibited the clinical pheno-
type of FH homozygotes while having normal LDLR activity
in cultured fibroblasts. Furthermore, genetic analysis did not
reveal any sequence alteration in the LDLR gene, thus
excluding the possibility that structural defects in the LDLR
protein might be responsible for the hypercholesterolemia. In
addition, abnormalities in apoB100 binding ability, as well as
the presence of sitosterolemia and CESD, were ruled out.
Plasma LDL-C levels are determined by the balance
between the production and the catabolic rate of LDL
particles.1 Therefore, to investigate the metabolic mecha-
nisms underlying this lipid disorder, we first determined the
in vivo kinetics of autologous 125I-LDL in 3 probands from
the 2 families. In all probands we found an average 50%
reduction in the FCRs of LDL apoB and a 40% increase in the
production rates of LDL apoB compared with controls. These
findings are different from those obtained in patients with
pseudohomozygous type IIA hyperlipoproteinemia, which
also shows severe hypercholesterolemia without evidence of
vertical transmission.27 Indeed, a 4-fold increase in LDL
production rate has been found in this disorder while LDL
catabolism is normal.28 Moreover, these patients are very
sensitive to a low-cholesterol diet and lipid-lowering drugs,
whereas our probands did not respond to either of these
treatments. Sirtori et al29 described the case of an Italian
woman with severe hypercholesterolemia, xanthomatosis,
coronary heart disease, and normal LDLR function. An LDL
turnover study showed a 3-fold increase in the LDL apoB
production rate (36.8 mg z kg21 z d21) while the FCR was
within normal limits. This pattern is clearly different from
that observed in our probands. Harada-Shiba et al30 recently
reported about 2 hypercholesterolemic Japanese brothers with
normolipidemic parents, clinical features of FH homozy-
gotes, and normal LDLR activity in fibroblasts. These authors
estimated from the rebound curve of plasma cholesterol after
plasmapheresis that cholesterol FCR was reduced (0.102
pool/d) while cholesterol synthesis was normal.
The most reasonable explanation for the association be-
tween low FCRs and increased LDL production rates in our
probands is a reduced LDLR activity. Indeed, in the case of
a reduction in LDLR activity, fewer VLDL remnants are
removed from the circulation and hence, more are converted
to LDL; such a phenomenon has been advanced for FH
homozygous patients.3 Therefore, the results of our 125I-LDL
turnover study seem to be consistent with an abnormal LDLR
activity. Nevertheless, this conclusion is in contrast with the
finding that the probands showed a normal LDLR activity in
cultured fibroblasts.
Because the liver is the major site of LDLR-mediated
catabolism,31,32 we investigated the possibility of a liver-
specific defect in LDL catabolism. To this aim, we injected
autologous 99mTc-LDL, a procedure that has been previously
demonstrated to allow the in vivo evaluation of lipoproteins.33
All probands showed a reduction in LDL liver uptake, as did
the FH homozygous subject. At the later time points, we also
observed a reduced LDL uptake by the spleen and kidneys. It
has been reported in animals that the spleen and kidney may
catabolize LDL.34 However, in our patients, the contribution
of these organs to LDL catabolism was small and might be
related, at least partially, to a scavenger receptor pathway.
On the whole, the results of this study are consistent with
the hypothesis that hypercholesterolemia in these kindreds is
caused by an inherited defect in LDL catabolism, which
appears to be expressed in hepatocytes but not in fibroblasts.
This defect cannot be explained by a disorder in the LDLR
gene itself but might be due to aberrant regulation of LDLR
gene expression. LDLR expression largely depends on the
intracellular cholesterol content35: an overaccumulation of
cholesterol in the hepatocytes suppresses LDLR activity.34
This accumulation could be due to abnormalities in (1) cho-
lesterol discharge and degradation through bile acids or
(2) regulation of cholesterol esterification.
The liver is the only organ that can excrete relatively large
amounts of cholesterol from the body, either directly or after
conversion to bile acids. This process is considered an
important regulatory step in the determination of cholesterol
balance. The synthesis of bile acids is carried out in the liver
by the action of at least 10 different enzymes, and cholesterol
7a-hydroxylase is the rate-limiting enzyme of this pathway.
By SSCP analysis, we were able to show that the 2 probands
from pedigree No. 1 (G.F.C. and J.C.) inherited different
alleles for the 7a-hydroxylase gene (H.H. Hobbs, personal
communication, 1998), excluding the possibility that a mu-
tation in this gene might be responsible for their disease.
Nevertheless, we could not definitively exclude the hypoth-
esis that an alteration in bile acid synthesis might be associ-
ated with this inherited disease. On the other hand, in a
previous description of Japanese siblings with similar char-
acteristics,30 no abnormality in whole-body cholesterol syn-
thesis, as estimated by urinary mevalonate excretion, could be
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demonstrated. Also, an abnormality in the regulation of
cholesterol esterification seems to be unlikely, because we
demonstrated that the esterification rate of cholesterol in
cultured fibroblasts from 1 of the probands was normal, thus
implying normal acyl coenzyme A cholesterol acyltransferase
activity.
The possibility that the defect we identified is due to some
alteration in the way that the hepatocytes “sense” intracellular
cholesterol is more intriguing. In this regard, an involvement
of the regulatory mechanism of LDLR gene expression
cannot be completely excluded, because alterations in differ-
ent trans-acting factors might affect this pathway indepen-
dently of the integrity of the LDLR gene itself. A pivotal role
in this pathway is played by sterol regulatory element binding
proteins 1 (SREBP1) and 2 (SREBP2).35 Defects in these
proteins might be responsible for an impairment of LDLR
gene expression. Nevertheless, by SSCP analysis, we have
demonstrated that G.F.C. and J.C. were heterozygous for
different alleles at both SREBP1 and SREBP2 loci (H.H.
Hobbs, personal communication, 1998), and this finding
would not be expected if the mutation were located in these
genes. Alternatively, the LDLR pathway might not be di-
rectly involved, and the disease may result from a defect in
another step of the intracellular metabolism of cholesterol
that specifically affects hepatocytes. An example of the
feasibility of this hypothesis is provided by the model
(HepG2 cell) in which LDLR activity is only slightly reduced
when 25-hydroxycholesterol or LDL is added to the medium,
unlike the response observed in fibroblasts.36 This difference
has been attributed to the subcellular compartmentalization of
cholesterol in the liver, with a relatively small pool being
critical for the regulation of LDLR activity; after passing
through the lysosomes, cholesterol must reach critical sites
before it can directly or indirectly affect receptor synthesis.37
A defect in this complex mechanism could lead to an
accumulation of cholesterol in the hepatocytes, with conse-
quent downregulation of LDLR activity.
In conclusion, we observed an unusual form of familial
hypercholesterolemia in 2 families of Sardinian origin, which
was caused by a selective reduction in the hepatic uptake of
LDL. On the basis of our data, we suggest that this disease
results from a suppression of LDLR activity in hepatocytes,
possibly due to a recessive defect in the regulation of cellular
cholesterol metabolism. Identification of the molecular basis of
this dyslipidemia is under active investigation. We propose to
identify this new clinical condition as “familial recessive
hypercholesterolemia.”
Note Added in Proof
At present, 4 new Sardinian families with the characteristics
of “familial recessive hypercholesterolemia” have been iden-
tified. In all probands, the LDLR activities in fibroblasts as
well as the binding ability of LDL to the LDLR are normal.
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